2020年限制性股票激励计划

Search documents
佰仁医疗: 佰仁医疗第三届监事会第七次会议决议公告
Zheng Quan Zhi Xing· 2025-06-13 09:19
Core Viewpoint - The company’s supervisory board has approved adjustments to its 2020 restricted stock incentive plan, including changes to the grant price and the status of unvested shares, ensuring compliance with relevant laws and regulations [1][2][3][4] Meeting Details - The third supervisory board meeting was held on June 13, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1] Resolutions Passed - The grant price for the 2020 restricted stock incentive plan was adjusted from 15.91 CNY per share to 15.11 CNY per share, with unanimous approval [2] - The board agreed to cancel a portion of the granted but unvested restricted stocks, which aligns with legal and regulatory requirements [2] - The fifth vesting period of the initial grant under the 2020 restricted stock incentive plan was confirmed to meet the vesting conditions, allowing 65 participants to vest 267,772 shares [3] - The third vesting period of the reserved grant under the 2020 restricted stock incentive plan was also confirmed to meet the vesting conditions, allowing 44 participants to vest 85,213 shares [4]
麦克奥迪: 关于作废2020年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Zheng Quan Zhi Xing· 2025-06-03 12:20
Core Viewpoint - The company has announced the cancellation of unvested restricted stock from the 2020 incentive plan due to various performance and employment-related reasons, affecting a total of 4,841,200 shares [1][8][9]. Summary by Sections 1. Approval Procedures for the 2020 Incentive Plan - The company held board and supervisory meetings in December 2020 to approve the 2020 restricted stock incentive plan and its related management measures [1][2]. - The list of incentive objects was publicly disclosed on December 21, 2020, with no objections received during the public comment period [2][3]. 2. Granting and Vesting of Restricted Stocks - The first grant of restricted stocks was approved in February 2021, with independent directors confirming the eligibility of the incentive objects [3][4]. - In September 2021, the company approved the granting of 1.7 million shares to 27 incentive objects [4]. 3. Adjustments and Cancellations - In May 2022, the company adjusted the grant price and announced the cancellation of unvested stocks from the 2020 plan [5][6]. - By June 2023, the company confirmed the vesting results for the second vesting period and announced further cancellations of unvested stocks due to performance issues and employee departures [6][7]. 4. Specifics of Canceled Restricted Stocks - The cancellation involved 2,227,400 shares from the first grant and 61,200 shares from the reserved grant, totaling 4,841,200 shares that could not vest due to unmet performance targets and employee status changes [8][9]. 5. Impact on the Company - The cancellation of these shares is not expected to materially affect the company's financial status or operational results, nor will it impact the stability of the management team [8][9]. 6. Opinions from Supervisory Board and Legal Advisors - The supervisory board has agreed to the cancellation based on the failure to meet performance targets, and legal advisors confirmed that the cancellation complies with relevant regulations [9][10].
合康新能: 第六届监事会第十八次会议决议公告
Zheng Quan Zhi Xing· 2025-05-16 11:10
Group 1 - The company held its 18th meeting of the 6th Supervisory Board on May 16, 2025, combining in-person and remote attendance, with all procedures complying with relevant laws and regulations [1] - The Supervisory Board approved the proposal to invalidate 475,000 unvested restricted stocks from the 2020 stock incentive plan, confirming it does not harm shareholder interests [1][2] - The Supervisory Board also approved the proposal regarding the fourth vesting period of the initial grant of the 2020 stock incentive plan, confirming that the vesting conditions have been met for 18 eligible participants [2]